natgillin/translations-raw huggingface dataset:
Ikke kendt (kan ikke vurderes ud fra tilgængelige data): - Kombination af omfattende svært udslæt, følelse af at være syg, feber, højt indhold af visse hvide blodlegemer eller gul hud eller øjne (tegn på gulsot) med stakåndethed, brystsmerter/ubehag, svært nedsat urinproduktion og tørst osv. (tegn på en behandlingsrelateret allergisk reaktion).
• Combination of a widespread severe rash, feeling sick, fever, high level of certain white blood cells or yellow skin or eyes (signs of jaundice) with breathlessness, chest pain/discomfort, severely decreased urine output and feeling thirsty etc. (signs of a treatment-related allergic reaction).
Svimmelhed, paræstesi, smagsforstyrrelser, hypoæstesi Migræne, døsighed, synkope, perifer neuropati, hukommelsessvigt, iskias, restless leg syndrome, tremor, hjerneblødning Øget interkranielt tryk, kramper, synsnervebetændelse
Dizziness, paraesthesia, taste disturbance, hypoaesthesia Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral haemorrhage Increased intracranial pressure, convulsions, optic neuritis
Børn: I studie I2301 blev der inkluderet i alt 93 børn, unge og yngre voksne (fra 1 til 22 år) med Ph+ ALL i et åbent, multicenter, ikke-radomiseret fase III sekventielt kohorte-forsøg.
Paediatric patients: In study I2301, a total of 93 paediatric, adolescent and young adult patients (from 1 to 22 years old) with Ph+ ALL were enrolled in an open-label, multicentre, sequential cohort, non-randomised phase III trial, and were treated with imatinib (340 mg/m2/day) in combination with intensive chemotherapy after induction therapy.
10 Muskuloskeletale smerter og relaterede hændelser blev observeret oftere hos patienter med CML end hos patienter med GIST.
10 Musculoskeletal pain and related events were more commonly observed in patients with CML than in
Det skal du vide, før du begynder at tage Imatinib Teva B.V.
What you need to know before you take Imatinib Teva B.V.
= intramuskulær, ARA-C = cytarabin, CPM = cyclophosphamid, VCR = vinkristin, DEX = dexamethason, DAUN = daunorubicin, 6-MP = 6-mercaptopurin, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2mercaptoethan-natriumsulfonat, iii= eller indtil MTX-niveauet er <0,1 μM, Gy= Gray.
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 µM, q6h = every 6 hours, Gy= Gray
Din læge vil fortælle dig om de mulige risici, der er forbundet med brug af Imatinib Teva B.V.
Your doctor will discuss with you the possible risks of taking Imatinib Teva B.V. during pregnancy.
Tredobbelt i.t.-terapi (aldersjusteret): dag 1 og 22 VP-16 (100 mg/m2/dag, i.v.
Triple IT therapy (age-adjusted): days 1 and 22 VP-16 (100 mg/m2/day, IV): days 22-26
• voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD)
- Myelodysplastic/myeloproliferative diseases (MDS/MPD).
anvendes også til behandling af voksne med: - Myelodysplastiske/myeloproliferative sygdomme (MDS/MDP).
Imatinib Teva B.V. is also a treatment for adults for: - Myelodysplastic/myeloproliferative diseases (MDS/MPD).
er en behandling mod: - Kronisk myeloid leukæmi (CML).
- Chronic myeloid leukaemia (CML).
C/C, n. 4, Poligono Industrial Malpica 50016 Zaragoza
C/C, n. 4, Poligono Industrial Malpica
meget sjælden (<1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Not known (frequency cannot be estimated from the available data):
Reaktivering af hepatitis B*
Description of selected adverse reactions Hepatitis B reactivation
Hvis cytopeni vedvarer i 2 uger, reducer dosis yderligere til 200 mg/m2.
If cytopenia persists for 2 weeks, reduce further to 200 mg/m2.
Aktive stoffer, der kan øge plasmakoncentrationen af imatinib Stoffer, der hæmmer CYP3A4-aktiviteten (f.eks. proteasehæmmere som f.eks. indinavir, lopinavir/ritonavir, ritonavir, saquinavir, teleprevir, nelfinavir, boceprevir; azol-antimykotika inklusive ketoconazol, itraconazol, posaconazol, voriconazol; visse makrolider som f.eks. erythromycin, clarithromycin og telithromycin), kan nedsætte metaboliseringen og øge koncentrationen af imatinib.
Active substances that may increase imatinib plasma concentrations Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations.
Der er kun begrænset erfaring med imatinib hos patienter med MDS/MPD forbundet med PDGFR-omlejring (se pkt.
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
cyster og polypper) Sjælden:
Neoplasm benign, malignant and unspecified (including cysts and polyps) Rare:
Palpitationer, takykardi, hjerteinsufficiens3, lungeødem Arytmi, atrieflimren, hjertestop, myokardieinfarkt, angina pectoris,
Palpitations, tachycardia, cardiac failure congestive3, pulmonary oedema Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction,
er 400 mg/dag for adjuverende behandling af voksne efter resektion af GIST.
The recommended dose of Imatinib Teva B.V. is 400 mg/day for the adjuvant treatment of adult patients following resection of GIST.
kan nedsætte antallet af hvide blodlegemer, så du lettere kan få infektioner.
Imatinib Teva B.V. can reduce the number of white blood cells, so you might get infections more easily.
(3 timer, q 12 timer), dag
(3 h, q 12 h), days
Alle patienter opnåede komplet hæmatologisk respons, cytogenetisk repons og/eller klinisk respons.
All patients achieved complete haematological response, cytogenetic response and/or
4.5), CYP3A4-substrater med et snævert terapeutisk vindue (f.eks. ciclosporin, pimozid, tacrolimus, sirolimus, ergotamin, dihydroergotamin, fentanyl, alfentanil, terfenadin, bortezomib, docetaxel, quinidin) eller warfarin og andre coumarin-derivater (se pkt.
(see section 4.5), CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).
Forhøjet serumkreatinin, forhøjet serumkreatinkinase og forhøjet serumlaktatdehydrogenase, forhøjet alkalisk fosfatase
Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase
Der ses generelt ingen bedring ved indgift af imatinib til patienter uden genetisk translokation.
Imatinib administration to patients without the genetic translocation generally results in no
Methylprednisolon 40 mg intrathecal, dag 1, 8, 15, 22
Methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22
er 600 mg/dag til voksne patienter i blastkrise.
The recommended dose of Imatinib Teva B.V. is 600 mg/day for adult patients in blast crisis.
er 600 mg/dag til voksne patienter med Ph+ ALL.
The recommended dose of Imatinib Teva B.V. is 600 mg/day for adult patients with Ph+ ALL.
Pleuraekssudat5, faryngolaryngeale smerter, pharyngitis Pleuralgi, lungefibrose, pulmonal hypertension, pulmonal blødning respirationssvigt11*, interstitiel lungesygdom* Kvalme, diarré, opkast, dyspepsi, abdominalsmerter6
Respiratory, thoracic and mediastinal disorders Pleural effusion5, pharyngolaryngeal pain, pharyngitis Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary Acute respiratory failure11*, interstitial lung disease* Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain6
- Muskelkramper eller led-, muskel- eller knoglesmerter, mens du er i behandling med Imatinib
• Muscle cramps or joint, muscle or bone pain, during treatment with Imatinib Teva B.V. or after you have stopped taking Imatinib Teva B.V.
(1 time) dag 4-5; i.v.
(1 h) days 4-5;
Der sås 4. grads neutropeni (ANC <0,5 x 109/l) og trombopeni (trombocyttal <10 x 109/l) hos henholdsvis 3,6% og <1% af patienterne med nydiagnosticeret CML i kronisk fase.
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/l) and thrombocytopenia (platelet count < 10 x 109/l) were observed in 3.6% and < 1% of patients, respectively.
MTX 15 mg intrathecal, dag 1;
MTX 12 mg intrathecal, day 1
Fra tilgængelige sikkerhedsdata ser det ikke ud til, at sikkerhedsprofilen for imatinib ændres ved optrapning af dosis til 800 mg daglig til patienter, hvis sygdom fremskrider ved de lavere doser på 400 mg eller 600 mg daglig.
From the safety data available, escalating the dose to 800 mg daily in patients progressing at lower doses of 400 mg or 600 mg daily does not seem to affect the safety profile of imatinib.
(24 timer), dag 4; DEX 40 mg/dag på dag 1-4 og 11-14, supplerende med MTX 1 g/m2
DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/m2 i.v.
Samtidig anvendelse af imatinib og lægemidler, der inducerer CYP3A4 (f.eks. dexamethason, phenytoin, carbamazepin, rifampicin, phenobarbital eller Hypericum perforatum, også kendt som prikbladet perikum) kan signifikant reducere følsomheden over for imatinib og dermed potentielt øge risikoen for terapeutisk svigt.
Concomitant use of imatinib and medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure.
ul.
GIST.
er nødvendig, skal overvåges tæt for tegn og symptomer på aktiv HBV-infektion i hele behandlingsperioden og i flere måneder efter behandlingsophør (se pkt.
Carriers of HBV who require treatment with Imatinib Teva B.V. should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).
Kronisk myeloid leukæmi er en type leukæmi, hvor nogle bestemte unormale hvide blodlegemer (der kaldes myeloide
Chronic myeloid leukaemia is a form of leukaemia in which certain abnormal white cells (named myeloid cells) start growing out of control.
Hvis noget af det ovenstående gælder for dig, skal du fortælle din læge det, før du tager Imatinib
If any of these apply to you, tell your doctor before taking Imatinib Teva B.V.
L-ASP (6.000 IE/m2, i.m.
L-ASP (6000 IUnits/m2, IM): day 44
Dosisjusteringer på grund af neutropeni og trombocytopeni
Dose adjustments for neutropenia and thrombocytopenia:
Ara-C 40 mg intrathecal, dag 1, 8, 15, 22;
Ara-C 40 mg intrathecal, days 1, 8, 15, 22;
Samtidig anvendelse af stærke CYP3A4 induktorer og imatinib bør
Therefore, concomitant use of strong CYP3A4 inducers and imatinib should be avoided (see section 4.5).
Pliva Hrvatska d.o.o.
PLIVA Croatia Ltd.
Der anbefales en dosis på 340 mg/m2
(starting dose 340 mg/m2)
(24 timer), dag 1, og Ara-C 2 g/m i.v.
(24 h), day 1, and Ara-C 2 g/m2 i.v.
Lægen vil fortælle dig, hvor mange Imatinib Teva B.V.-tabletter, du skal give dit barn.
The doctor will tell you how many tablets of Imatinib Teva B.V. to give to your child.
Din læge vil fortælle dig, præcis hvor mange Imatinib Teva B.V.-tabletter, du skal tage.
Your doctor will tell you exactly how many tablets of Imatinib Teva B.V. to take.
MTX 15 mg intrathecal, dag 1, 8, 15, 22;
MTX 15 mg intrathecal, days 1, 8, 15, 22;
Hvis cytopeni vedvarer i 2 uger, reducer dosis yderligere til 300 mg. 4.
If cytopenia persists for 2 weeks, reduce further to 300 mg. 4.
Hvornår og hvordan skal du tage Imatinib Teva B.V.
When and how to take Imatinib Teva B.V. - Take Imatinib Teva B.V. with a meal.
Brug af anden medicin sammen med Imatinib Teva B.V.
Other medicines and Imatinib Teva B.V.
Lægen vil fortælle dig, hvor mange Imatinib Teva B.V.-kapsler, du skal give dit barn.
The doctor will tell you how many capsules of Imatinib Teva B.V. to give to your child.
Hvis din daglige dosis er 800 mg (8 tabletter), skal du tage 4 tabletter om morgenen og 4 tabletter om aftenen.
If your daily dose is 800 mg (8 tablets), you should take 4 tablets in the morning and 4 tablets in
Spor af de opløste tabletter
Traces of the dissolved tablets may be left behind in the glass.
Pustuløst udslæt, kontusion, øget svedtendens, urticaria, ecchymose, let til knubs og mærker, hypotrichosis, hypopigmentering af huden, dermatitis exfoliativa, onychoclasi, folliculitis, petechier, psoriasis, purpura, hyperpigmentering af huden, bulløst udslæt Akut febril neutrofil dermatose (Sweets syndrom), misfarvning af negle, angioødem, vesikulært udslæt, erythema multiforme, leukocytoklastisk vasculitis, Stevens-Johnson syndrom, akut generaliseret eksantematøs
Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onychoclasis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions Acute febrile neutrophilic dermatosis (Sweet's syndrome), nail discolouration, angioneurotic oedema, rash vesicular, erythema multiforme, leucocytoclastic vasculitis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis (AGEP) Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and
daglig til børn med Ph+ ALL (totaldosis på 600 mg må ikke overskrides).
The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg).
G-CSF (5 μg/kg, s.c.): dag 27-36, eller indtil ANC >1500 post nadir ARA-C (3 g/m2, q 12 timer, i.v.
G-CSF (5 μg/kg, SC): days 27-36 or until ANC > 1500 post nadir ARA-C (3 g/m2, q12h, IV): days 43, 44
Anafylaktisk shock*
Anaphylactic shock* Blood and lymphatic system disorders
Din læge vil fortælle dig, præcis hvor mange Imatinib Teva B.V.-kapsler, du skal tage.
Your doctor will tell you exactly how many capsules of Imatinib Teva B.V. to take.
Farmakokinetik hos GIST-patienter
Pharmacokinetics in children
1Hæmatologiske responskriterier (hvert respons skal bekræftes ≥4 uger): CHR: Undersøgelse 0102 [ANC ≥1,5 x 109/l, trombocytter ≥100 x 109/l, ingen blaster i blodet, BM
CHR: In study 0102 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5%
100 mg filmovertrukne tabletter Pakningsstørrelser indeholdende 60 eller 120 filmovertrukne tabletter i blisterpakninger.
Imatinib Teva B.V. 100 mg film-coated tablets Pack sizes of 60 or 120 film-coated tablets in blisters.
DEX 10 mg/m2 oral, dag 1-5; CP 200 mg/m i.v., dag 3, 4, 5; MTX 12 mg intrathecal, dag 1
DEX 10 mg/m2 oral, days 1-5; CP 200 mg/m2 i.v., days 3, 4, 5;
Pakningsstørrelser indeholdende 20x1, 60x1, 120x1 eller 180x1 filmovertrukne tabletter i perforeret
Pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters.
Hvis du ved et uheld har indtaget for mange tabletter, skal du kontakte din læge med det samme.
If you take more Imatinib Teva B.V. than you should If you have accidentally taken too many tablets, talk to your doctor straight away.
Hvis du ved et uheld har indtaget for mange kapsler, skal du kontakte din læge med det samme.
If you take more Imatinib Teva B.V. than you should If you have accidentally taken too many capsules, talk to your doctor straight away.
100 mg hårde kapsler fås i blisterpakninger med 60 eller 120 hårde kapsler.
Imatinib Teva B.V. 100 mg hard capsules are available in pack sizes of 60 or 120 hard capsules in blisters.
er 100 mg/dag til voksne patienter med HES/CEL.
The recommended dose of Imatinib Teva B.V. is 100 mg/day for adult patients with HES/CEL.
- Hvis du behandles for Ph-positiv ALL: Startdosis er 600 mg, som skal tages som 6 kapsler én gang daglig.
- If you are being treated for Ph-positive ALL: The starting dose is 600 mg to be taken as 6 capsules once a day.
Alderen på disse patienter rangerede fra 2 til 16 år, og imatinib blev givet i en dosis på 300 mg/m2 dagligt eller doser,
The age of these patients ranged from 2 to 16 years and imatinib was given at dose 300 mg/m2 daily or doses ranging from 200 to 400
- Hvis du glemmer at tage en dosis, så tag den, så snart du kommer i tanker om det.
If you forget to take Imatinib Teva B.V. - If you forget a dose, take it as soon as you remember.
- Hvis du behandles for Ph-positiv ALL: Startdosis er 600 mg, som skal tages som 6 tabletter én gang daglig.
- If you are being treated for Ph-positive ALL: The starting dose is 600 mg to be taken as 6 tablets once a day.
Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om.
Check with your doctor or pharmacist if you are
Pakningsstørrelser indeholdende 20x1, 60x1, 120x1 eller 180x1 hårde kapsler i perforeret
Pack sizes of 20x1, 60x1, 120x1 or 180x1 hard capsules in perforated unit dose blisters.
Imatinib farmakokinetik
Population pharmacokinetics
ARA-C (3 g/m2/dosis q 12 timer x 4, i.v.
ARA-C (3 g/m2/dose q 12 h x 4, IV): days 2 and 3
Afvigelser i laboratorieværdier
Liver function tests
(1 time) dag 1; Ara-C 60 mg/m2 i.v., dag 22-25, 29-32 Konsoliderende behandling I, III, V MTX 500 mg/m2 i.v.
(24 h), days 1, 15; 6-MP 25 mg/m2 oral, days 1-20 Consolidation therapy II, IV Ara-C 75 mg/m2 i.v.
Hvis din daglige dosis er 800 mg (2 tabletter), skal du tage 1 tablet om morgenen og 1 tablet om aftenen.
If your daily dose is 800 mg (2 tablets), you should take one tablet in the morning and a second
400 mg filmovertrukne tabletter Pakningsstørrelser indeholdende 30 eller 90 filmovertrukne tabletter i blisterpakninger.
Imatinib Teva B.V. 400 mg film-coated tablets Pack sizes of 30 or 90 film-coated tablets in blisters.
Hvis cytopeni ikke er leukæmirelateret, reducer imatinib-dosis til 260 mg/m 3.
If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 260 mg/m 3.
Den filmovertrukne tablet har en længde på ca. 20 mm og en vidde på ca. 10 mm. Imatinib Teva B.V.
The length of the film-coated tablet is approximately 20 mm and the width is approximately 10 mm.
100 mg filmovertrukne tabletter fås i perforerede enkeltdosisblisterpakninger med 20x1, 60x1, 120x1 eller 180x1 filmovertrukne tabletter.
Imatinib Teva B.V. 100 mg film-coated tablets are available in pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters.
- Kraftige mavesmerter, blod i opkast, afføring eller urin, sortfarvet afføring (tegn på mave-tarm
• Severe abdominal pain, blood in your vomit, stools or urine, black stools (signs of gastrointestinal disorders).
(24 timer), dag 1, 15; oral, dag 1-20
(24 h), days 1, 15; 6-MP 25 mg/m2 oral, days 1-20
400 mg hårde kapsler fås i blisterpakninger med 30 eller 90 hårde kapsler.
Imatinib Teva B.V. 400 mg hard capsules are available in pack sizes of 30 or 90 hard capsules in blisters.
Pakningsstørrelser indeholdende 30x1 eller 90x1 filmovertrukne tabletter i perforeret
Pack sizes of 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.
beregnet til brug i den mest fremskredne fase af sygdommen (blastkrise).
In adult patients, Imatinib Teva B.V. is intended for use in the most advanced phase of the disease (blast crisis).
Den sædvanlige startdosis er 600 mg, som skal tages som 1 tablet a 400 mg og 2 tabletter a
The usual starting dose is 600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a
Ikke-transparent orange kapsel præget i sort blæk med 7629 på kapselbunden og præget i sort blæk med TEVA på kapselhætten.
Non transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap.
G-CSF (5 μg/kg, s.c.): dag 4-13, eller indtil ANC >1500 post nadir VCR (1,5 mg/m2/dag, i.v.
G-CSF (5 μg/kg, SC): days 4-13 or until ANC > 1500 post nadir VCR (1.5 mg/m2/day, IV): days 1, 8, and 15
CPM (250 mg/m2/dosis q12 timer x 4 doser, i.v.
CPM (250 mg/m2/dose q12h x 4 doses, iv): Days 3 and 4
Akut febril neutrofil dermatose (Sweets syndrom), misfarvning af negle, angioødem, vesikulært udslæt, erythema multiforme, leukocytoklastisk vasculitis, Stevens-Johnson syndrom, akut generaliseret eksantematøs
Acute febrile neutrophilic dermatosis (Sweet's syndrome), nail discolouration, angioneurotic oedema, rash vesicular, erythema multiforme, leucocytoclastic vasculitis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis (AGEP) Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and
- Kvalme opkastninger, diarré eller fordøjelsesbesvær.
• Feeling sick (nausea), being sick (vomiting), diarrhoea or indigestion.
Den sædvanlige startdosis er 600 mg, som skal tages som 1 kapsel a 400 mg og 2 kapsler a
The usual starting dose is 600 mg to be taken as one capsule of 400 mg plus 2 capsules of 100 mg
Hvis din daglige dosis er 800 mg (8 kapsler), skal du tage 4 kapsler om morgenen og 4 kapsler om aftenen.
If your daily dose is 800 mg (8 capsules), you should take 4 capsules in the morning and 4
Startdosis er 100 mg, som skal tages som 1 tablet a 100 mg én gang daglig.
The starting dose is 100 mg, to be taken as one tablet of 100 mg once a day.
Startdosis er 100 mg, som skal tages som 1 kapsel a 100 mg én gang daglig.
The starting dose is 100 mg, to be taken as one capsule of 100 mg once a day.
100 mg hårde kapsler Imatinib Teva B.V.
NAME OF THE MEDICINAL PRODUCT Imatinib Teva B.V. 100 mg hard capsules Imatinib Teva B.V. 400 mg hard capsules
400 mg hårde kapsler er uigennemsigtige orange kapsler, præget med 7630 med sort trykfarve på kapslens underdel og præget med TEVA på kapslens overdel.
Imatinib Teva B.V. 400 mg hard capsules are non-transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap.
er 400 mg/dag til voksne patienter med inoperable
The recommended dose of Imatinib Teva B.V. is 400 mg/day for adult patients with unresectable and/or
Hvis din daglige dosis er 800 mg (2 kapsler), skal du tage 1 kapsel om morgenen og 1 kapsel om aftenen.
If your daily dose is 800 mg (2 capsules), you should take one capsule in the morning and a
Ikke-transparent orange kapsel præget i sort blæk med 7630 på kapselbunden og præget i sort blæk med TEVA på kapselhætten.
Non transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap.
Hvis cytopeni ikke er leukæmirelateret, reducer imatinib-dosis til 400 mg. 3.
If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 400 mg. 3.
400 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 400 mg imatinib (som mesilat).
Imatinib Teva B.V. 400 mg film-coated tablets Each film-coated tablet contains 400 mg of imatinib (as mesilate).
(2 timer, q 12 timer), dag 23 (total af 8 omgange)
2-3 (total of 8 courses)
100 mg hårde kapsler er uigennemsigtige orange kapsler, præget med 7629 med sort trykfarve på kapslens underdel og præget med TEVA på kapslens overdel.
Imatinib Teva B.V. 100 mg hard capsules are non-transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap.
Stomatitis, mundulcera, gastrointestinalblødning7, sure opstød, melæna, betændelse i spiserøret, ascites, mavesår, hæmatemese, cheilitis, dysfagi,
Stomatitis, mouth ulceration, gastrointestinal haemorrhage7, eructation, melaena, oesophagitis, ascites, gastric ulcer, haematemesis, cheilitis,
100 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 100 mg imatinib (som mesilat).
Imatinib Teva B.V. 100 mg film-coated tablets Each film-coated tablet contains 100 mg of imatinib (as mesilate).
Din læge kan beslutte at øge dosis til 400 mg, som skal tages som 1 kapsel a 400 mg én gang daglig afhængig af, hvordan du responderer på behandlingen.
Your doctor may decide to increase the dose to 400 mg, to be taken as one capsule of 400 mg once a day, depending on how you respond to treatment.